论文部分内容阅读
目的分析高级别胶质瘤术后射波刀立体定向放射治疗、普通直线加速器同步放射治疗加化学治疗的临床疗效。方法将31例高级别胶质瘤患者分为射波刀立体定向放疗(射波刀)组16例、普通直线加速器放射治疗同步加化学治疗(普放)组15例。射波刀组用立体定向放疗技术,放疗剂量11.3Gy/天,连续3天,总剂量33.9Gy;普放组用调强放疗技术,2Gy/天·次,30次,总剂量60Gy,周一~周五治疗,期间连用替莫唑胺42天。两组均在放疗后用替莫唑胺辅助化疗6个疗程。用Kaplan-Meier法和COX模型进行生存分析。结果随访36~47(中位41)个月,射波刀组和普放组中位生存时间分别是15.55、14.7个月,1、2、3年生存率分别为56.3%、43.8%、37.5%及53.4%、40.2%、40.2%。两组对比,生存无明显差异(P>0.05)。结论高级别胶质瘤术后,采用射波刀立体定向放射治疗或者普通直线加速器同步放射治疗加化疗,后续联合辅助化疗,两者疗效无明显差别。
Objective To analyze the clinical curative effect of high-grade glioma after radiotherapy knife stereotactic radiotherapy and ordinary linear accelerator simultaneous radiotherapy plus chemotherapy. Methods Thirty-one patients with high-grade gliomas were divided into radiotherapy knife group (16 cases) and radiotherapy group (15 cases). Radiotherapy group with stereotactic radiotherapy technology, radiotherapy dose of 11.3Gy / day for 3 days, the total dose of 33.9Gy; general group with intensity-modulated radiotherapy, 2Gy / day times, the total dose of 60Gy, Friday treatment, during the use of temozolomide 42 days. Both groups were treated with temozolomide adjuvant chemotherapy for 6 courses after radiotherapy. Survival analysis was performed using Kaplan-Meier method and COX model. Results The median survival time was 15.55 and 14.7 months respectively between 36 and 47 (median 41) months after radiotherapy. The survival rates at 1, 2 and 3 years were 56.3%, 43.8% and 37.5 % And 53.4%, 40.2% and 40.2% respectively. There was no significant difference in survival between the two groups (P> 0.05). Conclusions After high-grade glioma surgery, radiosurgery using stereotactic radiotherapy or ordinary linear accelerator with simultaneous radiotherapy plus chemotherapy and subsequent adjuvant chemotherapy has no significant difference between the two groups.